Evidence map›Paper›PMID 32394047›Full record

ArticleInternational journal of clinical oncology2020

Efficacy and safety of nivolumab for renal cell carcinoma in patients over 75 years old from multiple Japanese institutes.

Kazuyuki Numakura, Mizuki Kobayashi, Shingo Hatakeyama, Sei Naito, Yohei Horikawa, Toshikazu Tanaka, Sachiko Kamada, Yumina Muto, Ryohei Yamamoto, Atsushi Koizumi and 9 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Aging, cancer, and antitumor immunity.International journal of clinical oncology · 2022
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 1 country.

Kazuyuki NumakuraDepartment of Urology, Akita University Graduate School of Medicine, Akita, Japan. numakura@doc.med.akita-u.ac.jp.ORCID http://orcid.org/0000-0002-5899-1738
Mizuki KobayashiDepartment of Urology, Akita University Graduate School of Medicine, Akita, Japan.
Shingo HatakeyamaDepartment of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Sei NaitoDepartment of Urology, Faculty of Medicine, Yamagata University, Yamagata, Japan.
Yohei HorikawaDepartment of Urology, Japanese Red Cross Akita Hospital, Akita, Japan.
Toshikazu TanakaDepartment of Urology, Aomori Prefectural Central Hospital, Aomori, Japan.
Sachiko KamadaDepartment of Neurology, Akita University Graduate School of Medicine, Akita, Japan.
Yumina MutoDepartment of Urology, Akita University Graduate School of Medicine, Akita, Japan.
Ryohei YamamotoDepartment of Urology, Akita University Graduate School of Medicine, Akita, Japan.
Atsushi KoizumiDepartment of Urology, Akita University Graduate School of Medicine, Akita, Japan.
Taketoshi NaraDepartment of Urology, Akita University Graduate School of Medicine, Akita, Japan.
Sohei KandaDepartment of Urology, Akita University Graduate School of Medicine, Akita, Japan.
Mitsuru SaitoDepartment of Urology, Akita University Graduate School of Medicine, Akita, Japan.
Shintaro NaritaDepartment of Urology, Akita University Graduate School of Medicine, Akita, Japan.
Takamitsu InoueDepartment of Urology, Akita University Graduate School of Medicine, Akita, Japan.
Naotake ShimodaDepartment of Urology, Japanese Red Cross Akita Hospital, Akita, Japan.
Norihiko TsuchiyaDepartment of Urology, Faculty of Medicine, Yamagata University, Yamagata, Japan.
Chikara OhyamaDepartment of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Tomonori HabuchiDepartment of Urology, Akita University Graduate School of Medicine, Akita, Japan.
Akita University · JPAkita Red Cross Hospital · JPHirosaki University · JPYamagata University · JPAomori Prefectural Central Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDespite nivolumab being increasingly used for treating metastatic renal cell carcinoma (mRCC), differing findings have been reported about its efficacy and safety in elderly patients. Thus, this study was aimed at evaluating nivolumab's efficacy and safety for treating mRCC in Japanese patients aged ≥ 75 years.

methodsFrom March 2013 to August 2019, 118 mRCC patients (89 men and 29 women) were treated with nivolumab. The objective response rates (ORRs) were compared between patients aged ≥ 75 and < 75 years. Progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were also compared between the two age-groups.

resultsThe median follow-up duration after nivolumab initiation was 10 months. At the time of nivolumab initiation, 22 and 96 patients were aged ≥ 75 and < 75 years, respectively. Intergroup differences in patient characteristics except for age were not significant. Furthermore, intergroup differences in ORR (14 vs 23%; P = 0.367), PFS (HR 0.74, 95% CI 0.37-1.51; P = 0.414), and median OS (HR 1.29, 95% CI 0.68-2.46; P = 0.433) were not significant. The incidence of nivolumab discontinuation due to AEs was significantly higher in the ≥ 75 years group (27% vs 7%; P = 0.028), although the intergroup difference in the AE incidence rate was not significant (55% vs 43.8%; P = 0.535).

conclusionsNivolumab's effectiveness was comparable between the two patient groups, except for early AE-related discontinuation in the ≥ 75 year group.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalAsian PeopleCarcinoma, Renal CellFemaleHumansKidney NeoplasmsMaleMiddle AgedNivolumabProgression-Free SurvivalRetrospective StudiesSurvival RateTreatment OutcomeAntineoplastic Agents, ImmunologicalNivolumab75 years or olderEfficacyNivolumabRenal cell carcinomaTolerability

Identifiers

PMID32394047
OpenAlexW3025264198

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.